REGULATORY UPDATE: FDA Finalizes Potency Assurance Guidance for Cellular and Gene Therapy Products

November 04, 2026

FDA’s Center for Biologics Evaluation and Research (CBER) issued a final guidance, Potency Assurance for Cellular and Gene Therapy Products. The guidance finalizes the December 2023 draft and replaces the January 2011 guidance, Potency Tests for Cellular and Gene Therapy Products.  

The new guidance applies to cellular and gene therapy (CGT) products regulated under section 351 of the Public Health Service Act. The document recommends a risk-based strategy that goes beyond lot release testing to include manufacturing process design, process and material controls, and in-process testing. The goal is to ensure every released lot can achieve its intended therapeutic effect. 

The final guidance keeps the draft’s framework but allows for more flexibility. “Phase-appropriate” expectations now appear throughout. FDA states that potency assurance can be built into a sponsor’s existing quality system and that the approach does not increase sponsor requirements. FDA also narrowed its clinical hold language. A hold is now tied to inadequate potency assurance that would expose subjects to unreasonable and significant risk, or to an IND missing required potency information. 

CBER Office of Therapeutic Products (OTP) is hosting a virtual public webinar on Thursday, Dec. 10 at 1:00 p.m. to highlight key considerations in the new final guidance.